Gilead Sciences, Inc. acquires Arcellx, Inc. for USD 7,100,000,000 (2026)

Deal facts

Buyer: Gilead Sciences, Inc.
Target: Arcellx, Inc.
Deal value: USD 7,100,000,000
Announced: 6 March 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

28 Apr 2026CompletedClosed
Ravens Sub, Inc completes acquisition of Arcellx, Inc.
Introductory Note. As previously disclosed on February 23, 2026 in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) by Arcellx, Inc., a Delaware corporation (the “ Company ”), the Company entered into an Agreement and Plan of Merger, dated as of February 22, 2026 (the “ Merger Agreement ”), by and among the Company, Gilead Sciences, Inc., a Delaware co
Source

OpinionExit Mode editorial

The completed acquisition of Arcellx, Inc by Parent for $7.1 billion marks a definitive shift in the healthcare sector. This transaction, announced on 6 March 2026, is a classic going-private deal structured with a mix of immediate cash and future earn-out payments. We see this as a clear signal that institutional capital is willing to pay a premium for control, provided the seller accepts performance-linked contingencies. The use of an earn-out mechanism suggests the buyer has identified specific commercial milestones they need to hit before releasing the full value. This is not merely a change of ownership; it is a recalibration of risk between the acquirer and the founders who built the asset.

For the SME founder reading this, the structure offers a vital lesson on valuation reality. A headline figure of $7.1 billion is attractive, yet the inclusion of an earn-out means the final price is not guaranteed. In the US market, where this deal closed, such arrangements are common when the target has high growth potential but uncertain near-term profitability. The buyer is effectively saying they will pay the full price only if the business performs as projected post-close. This creates a tension that founders must manage carefully. You are no longer running a public company with quarterly pressure, but you are now bound to private covenants that dictate your exit value. The regulatory context here involves standard change-of-control covenants and competition clearance, which have already been satisfied given the completed status.

We believe the path forward for founders in similar positions requires a shift in mindset from headline value to certainty of cash. The presence of an earn-out means you must negotiate the metrics that trigger those payments with the same rigour as the upfront price. Do not assume the buyer will automatically meet their targets or that the market conditions will remain favourable for the duration of the earn-out period. The deal mechanics are designed to protect the buyer, and your job is to ensure the triggers are within your control.

Your action item for this week is to review any current term sheets or live negotiations and isolate the specific performance metrics tied to any deferred consideration. If those metrics rely on external market factors or buyer integration success rather than your own operational delivery, you must demand a renegotiation or a higher upfront cash component to balance the risk.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Gilead Sciences, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history